rc48-adc
Fruquintinib
M.D. Anderson Cancer Centerantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
12 Active assets in the Fruquintinib cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Raltitrexed Meng Qiu | Phase 2 | CCC |
Fruquintinib Zhejiang University | Phase 2 | CCC |
Adebrelimab M.D. Anderson Cancer Center | Phase 2 | CCC |
Cetuximab Zhejiang University | Phase 2 | CCC |
S-1 Meng Qiu | Phase 2 | CCC |
View all 12 →
Same molecule, other indications
rc48-adc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →